| pubmed-article:19210138 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19210138 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:19210138 | lifeskim:mentions | umls-concept:C0242339 | lld:lifeskim |
| pubmed-article:19210138 | lifeskim:mentions | umls-concept:C0023779 | lld:lifeskim |
| pubmed-article:19210138 | lifeskim:mentions | umls-concept:C0360714 | lld:lifeskim |
| pubmed-article:19210138 | lifeskim:mentions | umls-concept:C0033363 | lld:lifeskim |
| pubmed-article:19210138 | lifeskim:mentions | umls-concept:C0449295 | lld:lifeskim |
| pubmed-article:19210138 | lifeskim:mentions | umls-concept:C1705938 | lld:lifeskim |
| pubmed-article:19210138 | lifeskim:mentions | umls-concept:C1527178 | lld:lifeskim |
| pubmed-article:19210138 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:19210138 | pubmed:dateCreated | 2009-2-12 | lld:pubmed |
| pubmed-article:19210138 | pubmed:abstractText | Several randomized controlled trials indicate that a low density lipoprotein cholesterol (LDL-C) target <2.0 mmol/L is appropriate for individuals at high risk of coronary artery disease (CAD). Recently released Canadian lipid management guidelines (2006) have incorporated this evidence into their recommendations. A cross-sectional study of patients treated with statins for at least 8 weeks (CALIPSO) was used as a basis to project the ability of statin monotherapy in getting high CAD-risk patients to an LDL-C level <2.0 mmol/L. | lld:pubmed |
| pubmed-article:19210138 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19210138 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19210138 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19210138 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19210138 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19210138 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19210138 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:19210138 | pubmed:issn | 1473-4877 | lld:pubmed |
| pubmed-article:19210138 | pubmed:author | pubmed-author:GagnéClaudeC | lld:pubmed |
| pubmed-article:19210138 | pubmed:author | pubmed-author:GenestJacques... | lld:pubmed |
| pubmed-article:19210138 | pubmed:author | pubmed-author:SebaldtRolf... | lld:pubmed |
| pubmed-article:19210138 | pubmed:author | pubmed-author:FodorGeorgeG | lld:pubmed |
| pubmed-article:19210138 | pubmed:author | pubmed-author:McPhersonRuth... | lld:pubmed |
| pubmed-article:19210138 | pubmed:author | pubmed-author:LavoieMarc-An... | lld:pubmed |
| pubmed-article:19210138 | pubmed:author | pubmed-author:SénécalMartin... | lld:pubmed |
| pubmed-article:19210138 | pubmed:author | pubmed-author:MarentetteMic... | lld:pubmed |
| pubmed-article:19210138 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19210138 | pubmed:volume | 25 | lld:pubmed |
| pubmed-article:19210138 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19210138 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19210138 | pubmed:pagination | 47-55 | lld:pubmed |
| pubmed-article:19210138 | pubmed:dateRevised | 2009-5-19 | lld:pubmed |
| pubmed-article:19210138 | pubmed:meshHeading | pubmed-meshheading:19210138... | lld:pubmed |
| pubmed-article:19210138 | pubmed:meshHeading | pubmed-meshheading:19210138... | lld:pubmed |
| pubmed-article:19210138 | pubmed:meshHeading | pubmed-meshheading:19210138... | lld:pubmed |
| pubmed-article:19210138 | pubmed:meshHeading | pubmed-meshheading:19210138... | lld:pubmed |
| pubmed-article:19210138 | pubmed:meshHeading | pubmed-meshheading:19210138... | lld:pubmed |
| pubmed-article:19210138 | pubmed:meshHeading | pubmed-meshheading:19210138... | lld:pubmed |
| pubmed-article:19210138 | pubmed:meshHeading | pubmed-meshheading:19210138... | lld:pubmed |
| pubmed-article:19210138 | pubmed:meshHeading | pubmed-meshheading:19210138... | lld:pubmed |
| pubmed-article:19210138 | pubmed:meshHeading | pubmed-meshheading:19210138... | lld:pubmed |
| pubmed-article:19210138 | pubmed:meshHeading | pubmed-meshheading:19210138... | lld:pubmed |
| pubmed-article:19210138 | pubmed:meshHeading | pubmed-meshheading:19210138... | lld:pubmed |
| pubmed-article:19210138 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19210138 | pubmed:articleTitle | Limitations of statin monotherapy for the treatment of dyslipidemia: a projection based on the Canadian lipid study--observational. | lld:pubmed |
| pubmed-article:19210138 | pubmed:affiliation | Health economics and outcomes research, Merck Frosst Canada Ltd., Montreal, Canada. martin_senecal@merck.com | lld:pubmed |
| pubmed-article:19210138 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19210138 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
